Pembrolizumab reduced recurrence risk of stage 3 melanoma
After a median follow-up of 15 months, 135 of the 514 patients treated with pembrolizumab
and 216 of the 505 patients treated with placebo
Pembrolizumab reduced recurrence risk of stage 3 melanoma
Food allergies may be triggered by genetic skin disorders, environmental factors
40% hydrogen peroxide vs. cryosurgery for seborrheic keratosis
Potential new formulation for treating allergic contact dermatitis
Rosacea Awareness Month highlights new standard classification, pathophysiology
MI contact allergy prevalence on rise in Western Canada
Melanoma: Obesity may provide a survival advantage
Chemical peels safe in darker skin